Funding for this research was provided by:
Takeda Pharmaceuticals (None)
Received: 23 July 2019
Accepted: 3 June 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: The study was approved by the local ethics committee at each participating site. Details on each study site and affiliated ethics committee study approval are provided in Additional file InternalRef removed. All patients alive at the time of chart abstraction (99% of patients) signed an informed consent form prior to participation in this study. No data from a deceased patient were included in the reported analyses.
: Not applicable.
: UH: Lecture fee(s) and consultancy: AbbVie, MSD, Ferring, Falk Foundation, Takeda, Mundipharma, Hospira, Vifor Pharma, Biogen, Pfizer, Shield Therapeutics, Janssen.MM: Consultancy: AbbVie, Takeda, MSD, Falk, Janssen, Pfizer.SS: Lecture fees: AbbVie, MSD, Falk, Ferring, Takeda, Janssen; consultancy: MSD, Janssen, Takeda, AbbVie.HH: Lecture fees: AbbVie, MSD, Falk, Ferring, Takeda; consultancy: AbbVie, Janssen, Takeda.AB: Employee of Takeda Pharma Vertrieb GmbH & Co. KG; holds Takeda stock or stock options.DS: Employee of Evidera, which received funds from Takeda to conduct the research.CK: Employee of Takeda Pharmaceuticals International AG; holds Takeda stock or stock options.JK: Employee of Takeda Pharma Vertrieb GmbH & Co. KG; holds Takeda stock or stock options.SCH: Employee of Takeda UK Limited; holds Takeda stock or stock options.RE: Lecture fee(s): AbbVie, Pfizer, MSD, Falk, Ferring, Takeda, Janssen, Hospira, Shield Therapeutics, Vifor Pharma, Tillotts Pharma AG, Recordati SpA, Norgine, Microbiotica, Ardeypharm; consultancy: MSD, Biogen, Ferring, Takeda, Janssen, AbbVie, Tillotts Pharma AG, Novartis.